Trial Profile
A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 20 Nov 2020 Status changed from recruiting to completed.
- 01 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 01 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.